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The TRAF3 molecule interacts with the cytoplasmic
carboxyl terminus (COOH terminus) of the Epstein-Barr
virus-encoded oncogene LMP-1. NF-kB activation is a
downstream signaling event of tumor necrosis factor
receptor-associated factor (TRAF) molecules in other
signaling systems (CD40 for example) and is an event
caused by LMP-1 expression. One region capable of
TRAF3 interaction in LMP-1 is the membrane-proximal
45 amino acids (188–242) of the COOH terminus. We
show that this region contains the only site for binding
of TRAF3 in the 200-amino acid COOH terminus of
LMP-1. The site also binds TRAF2 and TRAF5, but not
TRAF6. TRAF3 binds to critical residues localized be-
tween amino acids 196 and 212 (HHDDSLPHPQQAT-
DDSG), including the PXQX(T/S) motif, that share lim-
ited identity to the CD40 receptor TRAF binding site
(TAAPVQETL). Mutation of critical residues in the
TRAF3 binding site of LMP-1 that prevents binding of
TRAF2, TRAF3, and TRAF5 does not affect NF-kB-acti-
vating potential. Deletion mapping localized the major
NF-kB activating region of LMP-1 to critical residues in
the distal 4 amino acids of the COOH terminus (383–386).
Therefore, TRAF3 binding and NF-kB activation occur
through two separate motifs at opposite ends of the
LMP-1 COOH-terminal sequence.
LMP-1 is an essential gene for the immortalization of B cells
by Epstein-Barr virus in vitro (1) and functions as an oncogene
in rodent transformation assays (2–4). With the exception of
Burkitt’s lymphoma, LMP-1 is also expressed in all EBV1-
positive tumors where EBV is believed to play an etiologic role,
including nasopharyngeal carcinomas and Hodgkin’s disease
(5–7). The apparent oncogenicity of the LMP-1 gene product
has made this molecule the focus of intense interest in the field
of EBV biology.
LMP-1 is a short lived protein with a half-life of between 2
and 4 h (8, 9). This rapid turnover occurs due to the specific
cleavage in the COOH terminus at amino acid 242 resulting in
the release of a 144-amino acid 25-kDa fragment that is itself
rapidly degraded (10). LMP-1 is also selectively phosphorylated
in the released 25-kDa fragment at serine 311 and threonine
324 (11). The role of these modifications of the LMP-1 carboxyl
terminus are uncertain, although Thr-324 dephosphorylation
is required for the transformation of Rat-1 cells (11). Addition-
ally, immunohistochemical analysis of LMP-1 indicated that it
aggregates in the plasma membrane and co-patches with the
cytoskeletal protein vimentin (12). Patching of LMP-1 with
cytoskeletal components occurs through the cytoplasmic ami-
no-terminal residues (13). LMP-1 has thus been divided into
three separate domains, the cytoplasmic amino terminus, the
transmembrane, and the cytoplasmic carboxyl terminus.
All three domains of LMP-1 have been shown to be critical
for transformation in focus-forming assays with the rodent cell
line Rat-1 (14). The Rat-1 transformation assays were the first
formal demonstration that the COOH-terminal domain of
LMP-1 was critical to its function. These experiments delin-
eated critical residues for transformation to be present in the
last 23 COOH-terminal amino acids of LMP-1 (14), and addi-
tional unpublished studies suggested that the critical motif
includes the last 4 COOH-terminal amino acids. Subsequent
studies with recombinant virus confirmed the requirement for
COOH-terminal components of LMP-1 in the EBV immortal-
ization process during in vitro infection (15). The Rat-1 focus-
forming assay, therefore, has good predictive value for LMP-1
function.
LMP-1 has been the focus of recent intensive study due to its
ability to bind the family of adaptor molecules known as TRAFs
(TNF receptor-associated factors; reviewed in Ref. 16), specifi-
cally to TRAF3 (also known as LAP1, CRAF1, CD40bp, and
CAP1) (17–19). This is a significant finding, since it is known
that the phenotypic changes and activation state of an EBV-
infected cell is similar to that seen with CD40 receptor activa-
tion of B cells (20). CD40 receptor also binds to TRAF mole-
cules, and its functions are mediated through these molecules
(17, 18, 21). This is indirect evidence that EBV, specifically
LMP-1, may subvert normal cellular pathways to establish and
maintain the latent state of infection in B cells, as has been
hypothesized previously (22).
LMP-1 expression has been linked to many of the cellular
changes induced by EBV infection of B cells in vitro (reviewed
in Ref. 20). These include induction of activation and adhesion
markers (23–27) and Bcl-2 (28–30), changes in cellular prolif-
eration (31), and NF-kB activation (30, 32–37). Most of these
changes occur following stable or transient expression of
LMP-1 into tumor cell lines. However, it has been shown re-
cently that these changes, with the exception of NF-kB activa-
tion, are a consequence of LMP-1 overexpression in cell lines.2
NF-kB activation is therefore likely to represent the most rel-
evant measure of LMP-1 function.
The TRAF molecules are an expanding family of proteins
* This work was supported by U.S. Public Health Service Grants CA
31893 and CA 65883. The costs of publication of this article were
defrayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
¶ Present address: Dept. of Microbiology and Molecular Genetics,
UCLA, Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095.
i To whom correspondence should be addressed: Dept. of Pathology,
Tufts University School of Medicine, 136 Harrison Ave., Boston, MA
02111.
1 The abbreviations used are: EBV, Epstein-Barr virus; TRAF, TNF
receptor-associated factor; TNF, tumor necrosis factor; GST, glutathi-
one S-transferase; PCR, polymerase chain reaction; HA, hemaggluti-
nin; CMV, cytomegalovirus. 2 S. R. Brodeur and D. A. Thorley-Lawson, submitted for publication.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 272, No. 32, Issue of August 8, pp. 19777–19784, 1997
© 1997 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 19777
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on Decem
ber 29, 2006 
w
w
w
.jbc.org
D
ow
nloaded from
 
(TRAF1–TRAF6) that share a conserved COOH-terminal
TRAF domain (reviewed in Ref. 16). Most of these molecules
were identified due to their interaction with the TNF or CD40
receptors (17, 18, 38) but have been recently shown to also
interact with other TNF receptor family members such as
CD30 (39). TRAF2, TRAF5, and TRAF6 are the only members
able to directly cause activation of NF-kB through transient
overexpression (21, 40–42). TRAF2, TRAF3, and TRAF6 ap-
pear to be ubiquitously expressed, implying a general regula-
tory role, whereas TRAF1, TRAF4, and TRAF5 appear to be
more tissue-specific. Multimerization of the TRAF molecules
through the TRAF domain appears to be important for the
function of all of the TRAFs identified to date (21). A molecule
known as TANK or I-TRAF has also been identified that can
bind to TRAF molecules and appears to be a negative regulator
of the TRAF2, TRAF5, and TRAF6 NF-kB-activating function
(41, 43).
Analysis of the LMP-1 carboxyl terminus has identified two
regions that are potentially responsible for NF-kB activation.
One of these sites maps to the first 40–45 amino acids (188–
232) of the LMP-1 COOH terminus (33, 35), the same region
shown to be important in TRAF3 binding activity (19). A second
site maps to the last 35–45 amino acids (351–386) of the COOH
terminus of LMP-1 (33, 35). This site is dispensable for B
lymphocyte transformation (15) but correlates with sequences
that are essential for oncogenic transformation of Rat-1 cells
(14).
In this study we have dissected the cytoplasmic COOH ter-
minus of LMP-1 to attempt to understand the role of TRAF
binding in LMP-1 signaling functions. Preliminary sequence
analysis suggested three or four potential TRAF binding sites
in the COOH terminus of LMP-1. However, we localized the
sole recognition site for binding TRAF2, TRAF3, and TRAF5 to
the membrane-proximal region of the COOH terminus. Loss of
TRAF binding to this site does not affect LMP-1 activation of
NF-kB. A second distinct region, representing the major NF-
kB-activating sequence, is composed of critical residues that
include the last 4 amino acids of the LMP-1 COOH terminus.
These critical residues of LMP-1 are part of a sequence that
resembles a TRAF binding site, although TRAF2, TRAF3,
TRAF5, and TRAF6 do not bind, and correlate perfectly with
critical sequences shown previously to be essential in Rat-1
transformation assays.
EXPERIMENTAL PROCEDURES
Cell Lines—BJAB is a human EBV-negative lymphoblastoid B cell
line, and IB4 is an EBV-positive lymphoblastoid B cell line. Both were
maintained in RPMI 1640 and 10% fetal bovine serum (Sigma). 293
cells are a human embryonic kidney cell line and were maintained in
Dulbecco’s modified Eagle’s medium and 10% fetal bovine serum.
Plasmids and Constructs—GST fusion constructs were made by in-
serting PCR products of the LMP-1 COOH terminus into the EcoRI-
BamHI site of the pGEX2T (Pharmacia) multicloning site. For the
LMPC200 (from pB3LMP-1) and LMPN55 (from pB3LMP-1 del242–
386) fragments, engineered in frame 59 EcoRI and 39 BamHI sites were
added to the ends of the LMP-1 sequences 59-TATTACCATGGACAAC-
GACAC-39 and 59-GCCTATGACATGGTAATGCC-39, respectively. The
LMPC35 fusion used an engineered in frame 59 EcoRI site added to the
LMP-1 sequence 59-CATAGTCATGATTCCGGCCAT-39. The LMPC140
fusion was generated by cutting the LMPN55 PCR product with BglII
and BamHI and inserting this piece into the BamHI site of pGEX2T.
The BglII site was introduced into the LMPEnd (del242–386) construct
as described previously and cut to allow for an in frame sequence
starting at amino acid 245 of LMP-1. All PCR products were confirmed
by sequencing.
PCR mutagenesis was used to generate the LMPM2 and LMPEndM2
double point mutant constructs. The mutagenic oligonucleotides, 59-
CCTCAACAAGCTGCCGCGGATTCTGGCCAT-39 and its correspond-
ing opposite strand, were used with the above 59 EcoRI and 39 BamHI
primers by sequential PCR steps as described previously (48). The NcoI
fragment of the LMPM2 and LMPEndM2 PCR products were cloned
into the pB3LMP-1 construct to generate full-length coding sequence
containing the mutation.
MTLM (4) and the derivatives End (del242–386) and 4Stop (del364–
386) were described previously (14). LMP5Stop (del377–386) and
LMP6Stop (del383–386) deletions were created in the same way by
replacing coding sequence with stop codons using the Amersham in
vitro mutagenesis kit in the pB3LMP-1 vector as described previously
(14).
CMV LMP-1 constructs were derived by inserting the EcoRI (from
pB3LMP-1 MCS)-PvuII (LMP-1 noncoding) fragment of the various
LMP-1 mutants into the EcoRI-SmaI multicloning site of pCI-Neo
(Promega).
NF-kB transient transfections utilized the pIFNLuc and
pIFN(kB)3Luc (44). pCMVLuc was used as a positive control for lucif-
erase activity (gift of Dr. David Livingston), and pCMVbgal was used as
an internal control to normalize for transfection efficiency.
The vector for expressing FLAG-tagged human TRAF6
(pRK5FLAGTRAF6) (40) was a gift from Dr. David Goeddel (Tularik
Inc.). To produce human HA-tagged TRAF5, a cDNA for human TRAF5
was cloned into the vector pEBD (41). Oligonucleotides encoding the HA
tag were then cloned in frame at the 39-end of the TRAF5 cDNA
sequence.
Transfections—Transient transfection experiments in BJAB were
performed by electroporation of 5 3 106 cells at 300V/500 microfarads at
room temperature in the Bio-Rad Gene Pulser with 1–5 mg of the
appropriate vectors. Cells were harvested 24–48 h post-transfection in
300–400 ml of Reporter lysis buffer (Promega). All experiments repre-
sent three separate transfections with results done in duplicate.
GST Fusion Purification—GST fusion proteins were purified on glu-
tathione-Sepharose-4B beads (Pharmacia Biotech Inc.) as per the man-
ufacturer’s protocol from 1 liter of isopropyl-1-thio-b-D-galactopyrano-
side-induced culture. Following sonication of the cells to release the
GST proteins, 0.25 ml of washed packed bead volume was used for
purification. The coupled beads were then stored at 4 °C in phosphate-
buffered saline until they were used for in vitro binding assays.
In Vitro Binding Assays—Binding assays were done essentially as
described previously (45). In short, 293 cells, either stably or transiently
transfected with HA-tagged human TRAF2 (TRAF2/HA), TRAF3
(TRAF3/HA), or TRAF5 (TRAF5/HA) or FLAG-tagged TRAF6 (FLAG/
TRAF6) expression vectors, were lysed in Nonidet P-40 lysis buffer.
Lysates were incubated with appropriate GST fusion proteins coupled
to glutathione beads and washed four times with Nonidet P-40 lysis
buffer. Samples were then boiled in SDS sample buffer with 2-mercap-
toethanol and analyzed by SDS-polyacrylamide gel electrophoresis. Re-
solved proteins were transferred to nitrocellulose and probed with an-
ti-HA monoclonal antibody (Berkeley antibodies) or anti-FLAG M2
monoclonal antibody (Eastman Kodak Co., IBI) followed by a goat-anti
mouse immunoglobulin antibody coupled to horseradish peroxidase
(Sigma). Bound antibodies were detected with the ECL kit (Amersham
Corp.).
Luciferase Assays—50–200 ml of each extract (approximately 1–2 3
105 relative light units for pCMVLuc) was assayed using the Promega
luciferase assay system and a luminometer for detection. All extracts
were normalized for protein content using the Bradford assay (Bio-Rad)
and transfection efficiency by b-galactosidase activity (exogenous
pCMVbgal).
RESULTS
Identification of a TRAF3 Recognition Site in the LMP-1
COOH Terminus between Amino Acids 196 and 212—LMP-1
has been shown to interact with TRAF3 through its carboxyl-
terminal cytoplasmic tail. Previous studies (19) have shown
that TRAF3 binds to recombinant fusion proteins containing
either the full-length (200 amino acids from 188 to 386) or the
membrane proximal 44 amino acids (188–232) of the COOH
terminus of LMP-1. The number and specific sequences of
TRAF binding sites in the entire LMP-1 COOH terminus re-
mains to be elucidated.
We used the known TRAF3 binding sequence of the CD40
receptor COOH terminus to identify, by inspection, potential
TRAF3 binding sites in the COOH-terminal domain of LMP-1.
We found several likely regions with homology (Fig. 1A). Over-
all, the analysis revealed three potential TRAF3 binding sites,
designated LMP-1 A, B, and C, including one in the 44-amino
acid membrane proximal region (LMP-1 A). All three contained
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a conserved PXQX(T/S) motif in common with the CD40 recep-
tor. The sequences are shown aligned with the CD40 receptor
motif (in Fig. 1A), and their location in the LMP-1 COOH
terminus is shown at the top of Fig. 1B. To test the potential
TRAF3 binding capacity of each of these sites, we made a
number of GST fusion proteins containing various portions of
the LMP-1 sequence (Fig. 1B). The ability of these fusion pro-
teins to bind a recombinant TRAF3 protein fused to a hemag-
glutinin tag of influenza (TRAF3/HA) was then assessed using
an in vitro binding assay (see “Experimental Procedures”). The
results are shown in Fig. 2A. From these results, it is clear that
the only sites for TRAF3 binding in LMP-1 are present in the
first 55 amino acids (N55; residues 188–242), since no detect-
able binding to the C140 (residues 243–386) and C35 (residues
351–386) fusion proteins was seen. This indicates that the
LMP-1 B and C sites are not functional TRAF3 binding sites,
leaving LMP-1 A or other unspecified regions in N55 as candi-
date binding sites.
Alanine substitution studies of the TRAF binding site in the
CD40 cytoplasmic tail3 showed that substitution of any one of
three critical residues (shown in boldface type in Fig. 1A) in the
17-amino acid sequence of the CD40 receptor resulted in sig-
nificant loss of TRAF3 binding. Specifically, mutation of the
threonine residue at position 234 to alanine in the CD40 recep-
tor blocks both TRAF3 binding and CD40 functions (18, 46).
Use of a 17-amino acid synthetic peptide (N17) equivalent to
the LMP-1 A site of LMP-1 (residues 196–212) showed that this
region bound the TRAF3 protein (Fig. 2A) as well as or better
than N55. Introduction of a point mutation (equivalent to Thr-
234 in the CD40 receptor) into the 17-amino acid LMP-1 pep-
tide (N17M) by substitution of threonine 208 with alanine
caused an extensive reduction in TRAF3 binding (Fig. 2A). This
establishes that the LMP-1 A site, initially identified by se-
quence homology, is capable of binding to TRAF3.
The Amino Acids 196–212 Site Is the Only TRAF3 Recogni-
tion Site in the LMP-1 COOH Terminus—Having identified a
short peptide sequence between amino acids 196 and 212 that
was sufficient to bind TRAF3, we wished to establish if this was
the sole TRAF3 binding site in the entire LMP-1 COOH-termi-
nal sequence. This was done by testing if mutation of the motif
was able to block binding of TRAF3 to the intact COOH-termi-
nal domain. Based on mutagenesis studies of the CD40 recep-
tor, the introduction of two point mutations converting Thr-234
and Leu-235 to alanine was sufficient to completely inhibit
TRAF binding and CD40 functions (Fig. 2B). Therefore, we
introduced the equivalent mutations into the LMP-1 A motif in
3 G. Cheng and D. Baltimore, unpublished results.
FIG. 1. Identification of Potential TRAF3 binding sites in
LMP-1. A, the alignment of the putative 17-amino acid TRAF3 binding
sequences of LMP-1 with the known binding region of the CD40 recep-
tor. The LMP-1 A (amino acids 196–212), B (amino acids 312–328), and
C (amino acids 371–386) peptides shown, contain putative TRAF3 bind-
ing sites as defined by the highlighted PXQX(T/S) motif. This motif was
determined by visual inspection and comparison with the known
TRAF3 binding region of the CD40 receptor (CD40R) sequence. Aster-
isks label the critical residues in the CD40 receptor sequence as deter-
mined by alanine substitution experiments.3 B, the GST fusion proteins
modeled on the COOH-terminal regions of LMP-1. The full-length 386
amino acid LMP-1 sequence is shown (not to true scale) with the
relative positions of the three putative TRAF3 binding sites (A, B and C
peptides at the top). The GST portion of the fusions is linked to the
amino-terminal end of the LMP-1 fragments. The LMPC200 fragment
represents the full cytoplasmic COOH terminus of LMP-1 and contains
all three putative TRAF3 binding sites. The LMPN55 fragment con-
tains only one TRAF3 binding site (A peptide) and represents the
portion of LMP-1 remaining following cleavage. The LMPC140 and
LMPC35 fragments contain the other two putative TRAF3 binding sites
(B and C peptides). Highlighted residues in the peptide sequences at the
top of panel B show the positions of putative critical residues and the
PXQX(T/S) motif. LMPC140M2 and LMPN55M2 are the same as
LMPC140 and LMPN55 with the exception that two point mutations,
Thr-234 and Leu-235 to alanine, have been introduced into the LMP-1A
TRAF site. These mutations are sufficient to destroy the TRAF binding
capacity of this site. Abbreviations below the full-length LMP-1 are as
follows. N, the cytoplasmic N terminus; TM, the transmembrane region;
TRAF, the previously identified TRAF binding region; P, the sites of
phosphorylation; C, the COOH-terminal region previously shown to be
essential for Rat-1 transformation and NF-kB activation.
FIG. 2. In vitro binding assays of the GST-LMP-1 fusion pro-
teins with the TRAF3 molecule. A, in vitro binding assays define the
sole TRAF3 binding site in the LMP-1 COOH terminus. Various GST-
LMP fusion proteins were tested for binding to HA-tagged TRAF3 that
was stably transfected into the human embryonic kidney cell line 293.
Shown is an anti-HA Western blot to identify the ability of GST-LMP
fusion proteins to precipitate TRAF3 (TRAF3/HA) from a Nonidet P-40
lysate. LMPN55, LMPC140, and LMPC35 are described in the legend to
Fig. 1B and represent various fragments of the cytoplasmic COOH
terminus of LMP-1. The N17 and N17M lanes show the wild type 17
amino acid LMP-1 peptide A (residues 196–212) and the corresponding
peptide containing the mutation of threonine 208 to alanine, respec-
tively. B, in vitro binding assays show that point mutations in the
TRAF3 binding region preclude TRAF3 binding to the full COOH-
terminal sequences of LMP-1. Shown is the ability of CD40 receptor
cytoplasmic tail (CD40) to precipitate TRAF3 (TRAF3/HA) from Non-
idet P-40 lysates of the 293 cell line. The single point mutation of the
CD40 receptor at amino acid threonine 234 (CD40M) prevents TRAF3
binding. The full COOH terminus of LMP-1 (LMPC200) also binds
TRAF3, which can be abolished by the double point mutation at thre-
onine 208 and aspartic acid 209 (LMPC200M2).
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the GSTLMPC200 vector, converting the T-208 and D-209 res-
idues to alanine, generating the mutant GST fusion protein
LMPC200M2. The wild type and mutant fusion proteins were
then tested for binding to TRAF3 (Fig. 2B). The wild type
COOH-terminal domain of LMP-1 (C200) bound TRAF3 as
efficiently as the wild type CD40 receptor. However, the double
point mutation (C200M2) of the full-length carboxyl terminus
of LMP-1 completely ablates binding to TRAF3 (Fig. 2B). This
mutation does not show the weak binding that is displayed by
the single point mutation in the synthetic peptide (N17M) even
upon longer exposure. This is the first demonstration of point
mutations in the LMP-1 COOH-terminal cytoplasmic tail
(C200M2) that effectively knock out TRAF3 binding, therefore
confirming the presence of only one TRAF3 binding site (re-
ferred to as the TRAF3 recognition site).
Effect of TRAF3 Recognition Site Mutants on NF-kB Activa-
tion by LMP-1—Having identified the sole TRAF3 binding site
in the LMP-1 COOH terminus, we asked if mutations in this
site that prevent TRAF3 binding result in functional inactiva-
tion of LMP-1. Many functions have been attributed to ectopic
expression of LMP-1 in cell lines including induction of cell
surface activation and adhesion molecules, increased Bcl-2 ex-
pression, and NF-kB activation (reviewed in Ref. 20). Recent
evidence, utilizing an LMP-1-inducible system in the BJAB cell
line, showed that the only consequence of physiological levels of
expression of LMP-1 is the activation of NF-kB; the other
phenotypic effects occurred only at very high levels of LMP-1
expression that were also associated with the induction of
apoptosis.2 NF-kB activation is also a major function associated
with TRAF binding to TNF receptor family members including
CD40. We therefore used transient transfection studies in the
BJAB cell line to test for the functional role of the LMP-1
FIG. 3. TRAF3 binding to LMP-1 is
not sufficient to cause activation of
NF-kB. A, mutation of the sole TRAF3
binding site in the LMP-1 COOH termi-
nus does not block NF-kB activation.
Transient transfection of BJAB cells with
wild type full-length LMP-1 expressed
under the control of a strong promoter
(CMV LMP) causes NF-kB activation as
detected by luciferase reporter activity
with the IFN(kB3)Luc construct. The
TRAF3 site double point mutant of
LMP-1 (CMV LMPm2) does not prevent
the activation of NF-kB. The activating
heterodimer NF-kB pair of p50 and p65
(p50/p65) is a positive control for NF-kB
activation, and mock-transfected (Neo)
BJAB cells are a negative control to show
endogenous NF-kB activation. Luciferase
activity measured with the IFN promoter
construct in the absence of NF-kB en-
hancer sequences (IFNLuc) is also shown
to illustrate background promoter activ-
ity. NF-kB activity is reported as the nor-
malized luciferase activity of the NF-kB
reporter construct (IFN(kB3)Luc) versus
the normalized luciferase activity of the
promoter construct (IFNLuc) under the
same conditions (relative luciferase activ-
ity). B, binding of dominant negative
TRAF3 to the sole TRAF3 binding site of
LMP-1 does not block NF-kB activation.
Transient transfection of BJAB cells with
LMP-1 under the control of a weak pro-
moter (MTLM) activates NF-kB as meas-
ured with the IFN(kB3)Luc reporter. Co-
transfection of the dominant negative
TRAF3 molecule (C26 CRAF1/TRAF3)
under control of a strong promoter (over-
expression with CMV promoter) with the
LMP-1 expression vector (MTLM) does
not affect NF-kB activity. The same C26
TRAF3 construct under similar condi-
tions was previously shown to act as a
dominant negative molecule (17). The
EBV-positive lymphoblastoid cell line,
IB4, has been previously shown (34) to be
a good positive control for NF-kB activa-
tion. Mock-transfected BJAB acts as a
negative control to show endogenous
NF-kB activity of the cell line. All values
are reported as relative luciferase activity
as described in the legend to Fig. 3A.
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TRAF3 binding site in the activation of NF-kB.
Transient expression of the entire LMP-1 coding sequence
(CMVLMP) showed about a 15-fold induction of NF-kB from
the IFN(kB)3Luc construct (Fig. 3A) versus the IFNLuc con-
struct. This induction of NF-kB activity was equal to or perhaps
even higher than the activity produced by direct expression of
the p50 and p65 components of NF-kB. Transient expression of
the TRAF3 recognition site mutant (CMVLMPM2) produced
NF-kB activity comparable to that of wild type LMP-1. Repeat
experiments performed after different times of culture (24 and
36 h) gave comparable results, and overall, no significant dif-
ference in NF-kB activation was ever observed between the
wild type LMP-1 expression vector and the expression vector
expressing the mutant LMP-1 that could no longer bind
TRAF3. Therefore, the TRAF3 recognition site makes no de-
tectable contribution to the NF-kB activation associated with
LMP-1.
Truncated TRAF3 (C26 CRAF1; Ref. 17) is able to bind to its
recognition site and allows for homodimerization of the TRAF3
molecules, but it is no longer able to generate downstream
signals when receptors are stimulated. Loss of this activity
allows truncated TRAF3 to act as a dominant negative mole-
cule that, when highly overexpressed, will block the NF-kB-
and CD23-activating function of the CD40 receptor (17). To
further test the role of the LMP-1 TRAF3 site in NF-kB acti-
vation, LMP-1 was transiently expressed from the MTLM ex-
pression plasmid in the presence of co-transfected C26 at levels
previously shown to block CD40 signaling. Expression of
LMP-1 from the MTLM vector alone or in the presence of the
dominant negative TRAF3 produced comparable levels of NF-
kB, similar to those obtained with the EBV-positive lympho-
blastoid cell line IB4. This result confirms that the NF-kB-
activating function of LMP-1 does not require the TRAF3
recognition site.
Deletion Mapping Studies of the LMP-1 Sequence Required
for NF-kB Activation—Deletion mapping studies of LMP-1 us-
ing Rat-1 focus-forming assays provided the first demonstra-
tions that the COOH terminus of LMP-1 was required for
transformation (14). These studies mapped an essential do-
main for transformation by LMP-1 to the last 23 amino acids
(LMP del364–386-4 stop; Fig. 4A). Finer deletion mutants of
LMP-1 were also made (del377–386-5 stop and del383–386-6
stop), and these mutants were also unable to cause LMP-1-
induced transformation of Rat-1 cells.4 Subsequently, it was
demonstrated that the last 35–45 amino acids were also essen-
tial for NF-kB activation, raising the possibility that the
COOH-terminal motif identified in the Rat-1 assays was also
responsible for NF-kB activation. Therefore, we tested the non-
transforming deletion mutants in transient NF-kB assays to
see how closely the transforming ability of LMP-1 in Rat-1 cells
mapped to the site of NF-kB activation.
For these experiments a set of deletion mutants previously
constructed in the MTLM vector was used. Results of transient
transfection experiments in BJAB cells confirmed that the
lower levels of LMP-1 expression obtained with the MTLM
promoter nevertheless resulted in levels of NF-kB induction
similar to those obtained with the stronger CMV promoter
(Figs. 3A and 5A and data not shown).
We first tested the MTLMEnd deletion construct, which ex-
presses a truncated from of LMP-1 that lacks the COOH-
terminal 143 amino acids that constitute the p25 fragment that
is cleaved from LMP-1 at position 243 during the rapid turn-
over of LMP-1. This LMP-1 construct includes the TRAF3
binding site (Fig. 1B or 4A) but has been shown to be inactive
in the Rat-1 transformation assays. Therefore, the TRAF3 site
is insufficient to cause oncogenic transformation. As can be
seen from the lower part of Fig. 4B, the MTLMEnd construct is
also unable to activate NF-kB to levels higher than those ob-
tained from the endogenous NF-kB activity of BJAB cells. This
result confirms previous studies that have demonstrated the
requirement of the COOH-terminal 35–45 amino acids for
NF-kB activation. We have tested for NF-kB activity the three
most proximal COOH-terminal deletions (MTLM 4, 5, and 6
stop), all of which are inactive in RAT-1 transformation assays.
All of the LMP-1 deletion constructs tested, including the 6 stop
(del383–386) mutant, were unable to cause activation of NF-kB
over background levels seen in BJAB cells alone (CMVNeo).
The expression of LMP-1 protein from the MTLM 4, 5, and 6
stop constructs was confirmed by Western blot analysis (14);5
however, we have no antibody to confirm the expression of
MTLMEnd. It thus appears that constructs containing the
TRAF3 site but lacking the last four amino acids are inactive in
4 R. Moorthy and D. A. Thorley-Lawson, unpublished data.
5 S. R. Brodeur, G. Cheng, D. Baltimore, and D. A. Thorley-Lawson,
unpublished observations.
FIG. 4. NF-kB activation is localized to critical amino acids at
the distal COOH terminus of LMP-1. A, a series of mutants are
shown that delete 4 (6 stop), 10 (5 stop), or 23 (4 stop) amino acids from
the distal COOH terminus of the LMP-1 sequence. The 4 stop mutant
(del363–386) was previously shown to abolish the transforming ability
of LMP-1 in RAT-1 assays (14). The 5 stop and 6 stop mutants were
subsequently also shown to prevent transformation.4 B, COOH-termi-
nal deletions up to the last 4 amino acids of LMP-1 prevents the
activation of NF-kB. Expression of various COOH-terminal deletion
mutants under control of the weak MTLM promoter in a series of
transient transfections in the BJAB cell line showed that NF-kB acti-
vation is prevented. Mock-transfected (BJAB) cells are used to show
endogenous levels of NF-kB activity, and the full-length LMP-1 expres-
sion vector (MTLM) is used as a positive control. All values are reported
as relative luciferase activity as described in the legend to Fig. 3A.
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both NF-kB activation and Rat-1 transformation.
Analysis of the deleted sequences (Fig. 4A) reveals that the
distal COOH terminus of LMP-1 contained the putative TRAF
recognition site designated LMP-1 C in Fig. 1A based on the
presence of the PXQX(T/S) motif originally found in the CD40
receptor motif. The residues deleted in the 6 stop (del383–386)
mutant would delete two essential TRAF binding residues in-
cluding the critical T/S and adjacent amino acids. To date we
have tested TRAF2, TRAF3, TRAF5, and TRAF6 for their
ability to bind either the C140 or C35 construct (Figs. 1B, 2A,
and 6, Table I, and see below) and have consistently failed to
observe an interaction that could be mediated through the
LMP-1 C site. This site may therefore represent a binding
region important for interaction with as yet uncharacterized
TRAF molecules, or the presence of the motif may be fortuitous.
The TRAF3 Site Mediates NF-kB Activation When Overex-
pressed—The natural truncation of LMP-1 (MTLMEnd
(del242–386)) and the 4, 5, and 6 stop deletions do not induce
NF-kB (Fig. 4B) although they contain the TRAF3 binding site.
This is consistent with the failure of the TRAF3 point mutant
to block NF-kB activation and further supports the conclusion
that the TRAF3 binding site is not involved in activation of
NF-kB. This is contradictory to previous observations, how-
ever, which claimed that truncated LMP-1 could activate
NF-kB (33, 35, 47). In these studies, strong promoters were
used for LMP-1 expression. We have confirmed this as the
explanation for the discrepancy by repeating our experiments
using expression vectors with the strong CMV promoter in
place of the weaker MTLM promoter. As shown in Fig. 5,
expression of LMPEnd from a strong promoter can cause
NF-kB activation (CMVLMPEnd (del243–386)) to levels close
to those obtained with full-length LMP. This activity appears
to involve the TRAF3 site, since the introduction of point
mutations into the TRAF3 site of the LMPEnd construct
(LMPEndm2) results in a diminution of NF-kB activation.
The TRAF3 recognition site (exemplified by the LMPEnd
constructs) can therefore only stimulate NF-kB activity when
overexpressed (CMVLMPEnd).
TRAF2 and TRAF5 Bind to the TRAF3 Site—TRAF2,
TRAF5, and TRAF6, unlike TRAF3, can directly mediate
NF-kB activation. Therefore, we tested if any of these mole-
cules could bind to the potential TRAF binding sites in the
COOH terminus of LMP-1 thereby conferring NF-kB activa-
tion. Binding experiments with FLAG-tagged TRAF6 failed to
demonstrate any association between this molecule and any
portion of the LMP-1 COOH terminus (Table I and data not
shown). However, HA-tagged TRAF2 and TRAF5 gave results
essentially identical to those obtained with TRAF3 (Fig. 6 and
Table I). Only the membrane-proximal region (N55) bound
TRAF2 or TRAF5; there was no binding to the distal COOH-
terminal sequences (C140 and C35). In both cases, binding was
abolished upon mutation of the TRAF3 binding site (N17M,
N55M2, and C200M2) (Table I), showing that TRAF2 and
TRAF5 interact with this site. The only consistent difference
observed was that TRAF2 exhibits weaker binding to the
LMP-1 COOH terminus (C200 and N55) than TRAF3 and
TRAF5. This difference was not apparent in binding studies to
the CD40 receptor or to the isolated 17-amino acid LMP-1A site
(N17), suggesting that constraints on TRAF2 binding are im-
posed by the sequences flanking the TRAF binding site. The
binding of TRAF2 or TRAF5 probably accounts for the NF-kB
activation observed through the LMP-1A TRAF binding site
when expressed at high levels. However, neither TRAF2,
TRAF5, nor TRAF6 can account for activation of NF-kB
through the distal COOH terminus of LMP-1, since we have
never observed binding of any of these molecules to this
domain.
These results taken together are consistent with the idea
that overexpressed truncated LMP-1 (LMPEnd) can recruit
enough TRAF2 or TRAF5 to cause potentially artifactual acti-
vation of NF-kB. We conclude, therefore, that TRAF2, TRAF3,
TRAF5, and TRAF6 play no significant role in the NF-kB-
activating potential of LMP-1.
DISCUSSION
The COOH-terminal domain of LMP-1 is essential for its
biological activity including immortalization of B cells, trans-
formation of rodent fibroblasts (Rat-1), and activation of NF-
kB. Deletion mapping studies using the Rat-1 focus-forming
assays showed that critical residues in the COOH-terminal 23
amino acids were essential for transformation (14), thus map-
ping a critical domain for the oncogenic function of LMP-1.
FIG. 5. Overexpression of LMP-1 al-
lows for activation through the
TRAF3 binding site. Overexpression of
the natural truncation of LMP-1 is able to
allow for activation of NF-kB through the
TRAF3 site. Transient transfection of
BJAB cells with LMP-1 expression vec-
tors containing a strong promoter (CMV)
showed that the TRAF3 site in the trun-
cated LMP-1 construct (CMV LMPEnd) is
able to stimulate NF-kB activity (36 h) as
well as the wild type (CMV LMP). The
LMPEnd stimulation of NF-kB activity
could be diminished by mutation of the
TRAF3 site (CMV LMPEndm2), whereas
it had no effect on NF-kB activation by
the full-length LMP-1 as shown in Fig. 3.
The heterodimer pair of NF-kB molecules
(p50 and p65) transfected into BJAB cells
were used as a positive control, and mock-
transfected (Neo) BJAB cells were used as
a negative control for NF-kB activation.
All values are reported as relative lucifer-
ase activity as described in the legend to
Fig. 3A.
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Subsequent studies showed that the COOH-terminal 35–45
amino acids were also required for NF-kB activation. Following
the results of the Rat-1 studies, recombinant virus experiments
confirmed the importance of the COOH-terminal domain of
LMP-1 (15) by showing it was essential for B cell immortaliza-
tion. The later studies additionally mapped a second essential
site to the membrane-proximal 44 amino acids (188–232) that
was subsequently shown to bind TRAF3 (19). In this present
study, we have identified the critical residues for the TRAF3
binding site and a second, discrete, distal COOH-terminal site
essential for inducing NF-kB activity. This demonstrates that
the TRAF3 binding site does not play a critical role in NF-kB
activation and that the LMP-1 COOH terminus has two do-
mains that are both critical for its transforming potential. In
particular, the NF-kB-activating site would appear to be essen-
tial for the oncogenic activity of LMP-1 based on Rat-1 trans-
formation assays. It is thus surprising that recombinant virus
studies have suggested that this domain is not essential for B
cell immortalization (15). It seems more likely that both re-
gions working in concert are responsible for the transforming
or immortalizing activity of LMP-1.
The association of TRAF3 with the cytoplasmic COOH ter-
minus of LMP-1 and the ability of LMP-1 to induce NF-kB
activity in a large variety of cell lines has led to the suggestion
that TRAF signaling can mediate this event. Work from a
number of labs indicates that of the TRAF family members
identified thus far, only the TRAF2, TRAF5, and TRAF6 mol-
ecules are capable of directly causing induction of NF-kB ac-
tivity. TRAF3 would therefore not be expected to be an active
participant in NF-kB induction through LMP-1. So how does
LMP-1 effect induction of NF-kB activation?
There is the possibility that TRAF2 or TRAF5 could mediate
NF-kB signaling through binding to the TRAF3 recognition
site. This is unlikely, however, because we detect no activation
of NF-kB through the TRAF3 recognition site unless LMP-1 is
overexpressed. We have also shown that this is the only site for
binding the known TRAF molecules in the entire COOH-ter-
minal domain and that mutation of the binding site completely
ablates TRAF binding without affecting NF-kB activation.
Therefore, TRAF2 or TRAF5 binding to the TRAF3 recognition
site in LMP-1 cannot account for a significant amount of NF-kB
activation.
What is clear from our work is that the major NF-kB-acti-
vating potential is localized to critical residues in the last few
amino acids of LMP-1, but how these residues achieve this is
unknown. By inspection, the major NF-kB-activating sequence
has similarity to the TRAF binding site, although it does not
bind TRAF2, TRAF3, TRAF5, or TRAF6. It is possible that this
site can bind as yet uncharacterized TRAF molecules. This is
consistent with recent evidence (47) demonstrating that the
general TRAF inhibitor molecule, TANK/I-TRAF can block in-
duction of NF-kB and that the dominant negative TRAF2
del6–86 can partially inhibit NF-kB activation. How the
TRAF2 dominant-negative molecule mediates this weak inhi-
bition of LMP-1-induced NF-kB activity is unclear given the
inability of TRAF2 to bind to this region. It is likely, therefore,
that another TRAF molecule will be implicated as the respon-
sible factor. We have identified critical amino acid residues for
TRAF binding in the TRAF3 recognition site of LMP-1, and we
are currently deriving point mutations of the distal COOH-
terminal site. These mutations should help identify the critical
residues and establish the relevance of this second putative
TRAF binding site.
Finally, a number of laboratories have reported that the
region of LMP-1 containing the TRAF3 recognition sequence
can mediate induction of NF-kB activity. The data on the abil-
ity of the TRAF3 recognition site to cause NF-kB activation are
conflicting. All reports to date (33, 35) suggest that activation of
NF-kB with truncated forms of LMP-1 containing sequences up
to the first 45 amino acids of the COOH terminus (equivalent to
LMPEnd in our studies) occurs at 25–50% of the level of full-
length LMP-1. Our results show this same effect, but only in
the case where LMP-1 is overexpressed (CMV-driven con-
structs). In contrast to this, when lower expression levels are
used, the induction of NF-kB activity is only detected with
FIG. 6. In vitro binding assays of the GST-LMP-1 fusion pro-
teins with the TRAF5 molecule. In vitro binding assays demonstrate
that TRAF5 binds to the same site in the LMP-1 COOH terminus as
TRAF3. Various GST-LMP fusion proteins were tested for binding to
HA-tagged TRAF5 that was stably transfected into the human embry-
onic kidney cell line 293. Shown is an anti-HA Western blot to identify
the ability of GST-LMP fusion proteins to precipitate TRAF5/HA from
a Nonidet P-40 lysate. LMPN55, LMPN55M2, LMPC140, and LMPC35
are described in Fig. 1B and represent various fragments of the cyto-
plasmic COOH terminus of LMP-1. LMPN55M2 is the same as
LMPN55 except that two critical residues in the TRAF3 binding site
have been mutated so that it can no longer bind TRAF3. CD40 is the
cytoplasmic tail of the human CD40 receptor.
TABLE I
Summary of in vitro binding assays with GST-LMP fusion proteins to
the TRAF2 and TRAF3 molecules
Table gives summary of results of Western blots showing in vitro
binding of TRAF2, TRAF3, TRAF5, and TRAF6 in Nonidet P-40 lysates
of transfected 293 cells with LMP-1 fusion proteins. 1 indicates detect-
able binding of LMP-1 or CD40 receptor fusion peptides to TRAF
molecules. The extent of TRAF binding is depicted by multiple 1 signs,
with 111 being the highest binding detected and 1 being the lowest
detectable binding. The relative binding indicated by the plus signs can
be seen by comparing Table I and Fig. 2. The GST-LMP fusions are as
described in Fig. 1B. ND, not detected.
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full-length LMP-1. The likely explanation for this is that
NF-kB induction through the TRAF3 site is an artifact induced
by overexpression of truncated LMP-1. If the TRAF3 recogni-
tion site binds TRAF3 almost exclusively, NF-kB activity would
not be expected to occur through this site, consistent with the
TRAF3 site mutant being fully active in NF-kB activation. An
artifact from the overexpression of truncated LMP-1 could oc-
cur if sufficient TRAF2 is bound such that a signal can be
generated to activate NF-kB. Recent evidence (47) supports
this interpretation, since a dominant negative TRAF2 (del6–
86) completely blocks activation of NF-kB by truncated LMP-1
(LMP del232–386). The complete block of NF-kB activation by
this TRAF2 mutant indicates that the signal generated is spe-
cifically due to the ability of TRAF2 to bind to the TRAF3 site.
The demonstration that high level expression of LMP-1 may
lead to nonphysiologic activation of NF-kB through artifactual
TRAF2 binding is also of considerable importance in providing
a mechanism for understanding our recent observations that
many of the phenotypic effects of LMP-1 expression detected by
transfection studies in B cell tumor lines are only seen at high
levels of LMP-1 expression. Only NF-kB activation was ob-
served at the levels of expression found in lymphoblastoid cell
lines. This is entirely consistent with our observation that
NF-kB activation at moderate levels of LMP-1 expression ap-
pears to occur exclusively through the distal COOH-terminal
site (amino acids 383–386). At high levels, the signaling
through the TRAF3 site is probably corrupted, leading to other
phenotypic effects. It is perhaps not surprising that one of these
effects is the induction of apoptosis.
TRAF3 binding and the TRAF3 recognition site in LMP-1
therefore are unlikely to play a role in NF-kB activation. This
does not rule out a potential role for TRAF3 binding in the
transforming ability of LMP-1. This role is evidenced by recom-
binant virus studies (15), but the mechanism by which TRAF3
achieves immortalization through LMP-1 is unknown. Future
experiments will focus on the transforming potential of TRAF3
binding site mutants using the ability of LMP-1 transfected
epithelial cell lines to cause tumorigenesis in SCID mice (49).
To date, it has been shown that LMP-1 undergoes specific
cleavage and phosphorylation and binds TRAF3, but no clear
downstream consequences of these events have been demon-
strated. At this time, there is no mechanism to explain how
these modifications occur, but point mutation of critical signal-
ing motifs may lead to answers. It will be interesting to see if
biochemical modifications of the LMP-1 COOH terminus will
be affected by loss of TRAF3 binding or loss of NF-kB-activat-
ing potential.
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